It is interesting to mention that treatment with inhibitors of the TGF-β pathway, such as Galunisertib (LY2157299–a selective ATP-mimetic inhibitor of TGF-β receptor I) decreased the stemness related genes of mesenchymal HCC cells and their ability to form colonies, liver spheroids and invasive growth (185). The gene discussed is TGFB1; the disease is hepatocellular carcinoma.